Industry Veterans Appointed to Head the Global Technical Operations and Clinical Development Organizations at Kite
November 21 2019 - 8:30AM
Business Wire
-- Charles Calderaro and Ken Takeshita, MD
to Join Kite’s Leadership Team --
Kite, a Gilead Company (Nasdaq: GILD), today announced two new
additions to the company’s leadership team. Charles Calderaro will
join Kite as Global Head of Technical Operations, and Ken
Takeshita, MD will join as Global Head of Clinical Development.
Both Mr. Calderaro and Dr. Takeshita will report directly to
Christi Shaw, Chief Executive Officer of Kite.
“Innovation in manufacturing and scientific advancement are
dually critical to the delivery and continued progress of cell
therapy,” said Ms. Shaw. “We are pleased to welcome Charles and
Ken, whose deep and diverse experience will bolster Kite’s
leadership in cell therapy and ensure that we are best positioned
to meet the needs of patients now and well into the future.”
Mr. Calderaro will be responsible for leading all aspects of
Kite’s technical operations, including process development,
manufacturing, supply chain management, quality assurance and
end-to-end optimization for the company’s commercial and pipeline
products, effective December 9, 2019. He joins Kite from BioMarin
Pharmaceutical Inc., where he currently holds the position of
Senior Vice President, Global Manufacturing and is responsible for
the strategic oversight and leadership of the company’s
international operations network. Previous to this, Mr. Calderaro
was the Vice President of Technical Product Management at Genentech
leading the CMC life cycle management of the company’s small
molecule product portfolio in Basel, Switzerland.
“I am impressed with Kite’s R&D and manufacturing
excellence, which have had a dramatic impact on the treatment of
cancer and really helped set the company apart,” said Mr.
Calderaro. “I look forward to bringing my experience to the company
and to working with the many talented individuals dedicated to
changing the way this disease is treated.”
Dr. Takeshita will head Kite’s cell therapy clinical development
organization, including the company’s pipeline in solid tumor
research, effective December 3, 2019. He joins Kite from Sorrento
Therapeutics, Inc., where he is currently Senior Vice President,
Clinical Research, responsible for clinical development strategy in
oncology. His previous experience includes many years at Celgene
Corporation, where he was Corporate Vice President for Clinical
R&D and the Therapeutic Area Head for Lymphoma and CLL.
“It is a privilege to have the opportunity to contribute to
Kite’s industry-leading cell therapy clinical development program,”
said Dr. Takeshita. “I am excited by the company’s pipeline and
consistent commitment to next-generation science, and look forward
to helping further the team’s collective mission.”
About Kite
Kite, a Gilead Company, is a biopharmaceutical company based in
Santa Monica, California. Kite is engaged in the development of
innovative cancer immunotherapies. The company is focused on
chimeric antigen receptor and T cell receptor engineered cell
therapies. For more information on Kite, please visit
www.kitepharma.com.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com.
For more information on Kite, please visit the
company’s website at www.kitepharma.com. Learn more about Gilead at
www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call
Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191121005296/en/
Greg Mann, Investors (424) 322-1795
Shant Salakian, Media (424) 384-1841
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024